The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.
Medical device firm Cooper Companies has agreed to acquire the global rights to Teva’s Paragard intrauterine device (IUD) for $1.1 billion.
AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
The Indian Patent Office has approved pharmaceutical company Pfizer’s application to patent its Prevenar 13 (pneumococcal 7-valent conjugate) drug, despite claims by Médecins Sans Frontières that it is too obvious.
The creator of OmniRat, the first human monoclonal antibody technology based on rats, outlined the success story of the project yesterday at the 2017 BIO International Convention.
Genome editing company Intellia Therapeutics has been granted a patent from China’s State Intellectual Property Office covering the CRISPR/Cas9 technology.
The World Intellectual Property Organization’s Re:Search has launched a new five-year guide to its activities in the fight against neglected tropical diseases, malaria and tuberculosis.
The World Health Organization will launch a pilot project for biosimilars to make costly cancer treatments more widely available in low and middle income countries.
Japan-based Sawai Pharmaceutical has agreed to buy the generic drugs business of Upsher-Smith Laboratories for nearly $1.1 billion.
Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.